Dysregulated FOXO1 activity drives skeletal muscle intrinsic dysfunction in amyotrophic lateral sclerosis
Authors:
- Mónica ZufiríaMZMónica Zufiría
- Oihane Pikatza-MenoioOPOihane Pikatza-Menoio
- Maddi Garciandia-ArcelusMGMaddi Garciandia-Arcelus
- Xabier BengoetxeaXBXabier Bengoetxea
- Andrés JiménezAJAndrés Jiménez
- Amaia EliceguiAEAmaia Elicegui
- Maria LevchukMLMaria Levchuk
- Olatz Arnold-GarcíaOAOlatz Arnold-García
- Pablo IruzubietaPIPablo Iruzubieta
- Jon OndaroJOJon Ondaro
- Uxoa Fernández-PelayoUFUxoa Fernández-Pelayo
- Mikel Muñoz-OrejaMMMikel Muñoz-Oreja
Preprint
Abstract
Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS . We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs ( TBPH or caz ) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.Keywords
This publication has 91 references indexed in Scilit:
- Loss of TDP-43 splicing repression occurs early in the aging population and is associated with Alzheimer’s disease neuropathologic changes and cognitive declineActa Neuropathologica, 2023
- C-terminal frameshift variant of TDP-43 with pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTDActa Neuropathologica, 2023
- TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral SclerosisJAMA Neurology, 2022
- Muscle cells of sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesiclesJournal of Cachexia, Sarcopenia and Muscle, 2022
- ERK3‐MK5 signaling regulates myogenic differentiation and muscle regeneration by promoting FoxO3 degradationJournal of Cellular Physiology, 2022
- MEF2 impairment underlies skeletal muscle atrophy in polyglutamine diseaseActa Neuropathologica, 2020
- FOXO transcription factors at the interface of metabolism and cancerInternational Journal of Cancer, 2017
- Predicting disease progression in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology, 2016
- FoxO transcription factors: their roles in the maintenance of skeletal muscle homeostasisCellular and Molecular Life Sciences, 2013
- Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF‐κB‐independent, FoxO1‐dependent mechanismJournal of Cellular Physiology, 2006